Please login to the form below
Crucell
This page shows the latest Crucell news and features for those working in and with pharma, biotech and healthcare.
Janssen’s quest to prevent diseases taking hold
Janssen’s acquisition of Crucell in 2011 brought it a suite of promising platforms covering HIV, a universal flu vaccine, respiratory syncytial virus (RSV), which is an infection of the lungs
Latest news
-
Ebola vaccine halt 'a precaution' say researchers
Meanwhile, Johnson &Johnson (J&J) is also stepping up production of its own candidate - being developed by subsidiary Crucell in partnership with the Danish biotech Bavarian Nordic and the US National
-
J&J to produce one million doses of Ebola vaccine
The vaccine is being developed by J&J's Netherlands-based subsidiary Crucell in partnership with the Danish biotech Bavarian Nordic and the US National Institutes of Health (NIH). ... It combines Crucell's AdVac technology and Bavarian Nordi's MVA-BN
-
J&J fast-tracks Ebola vaccine
The US-based healthcare giant's subsidiary Crucell – based in the Netherlands – is collaborating with the Danish biotech Bavarian Nordic on a combination vaccine regimen with clinical trials in humans planned ... So far the regimen – which combines
-
Chugai appoints US CMO
At Merck Serono he served as head of clinical development for small molecules in onco-haematology and his prior experience includes clinical roles across Europe at Novartis, Crucell, Bavarian Nordic and
-
Janssen boosts vaccines pipeline with GlycoVaxyn deal
Its early development will see GlycoVaxyn collaborate with Janssen's vaccines- focused affiliate Crucell, but once the programme enters later-stage clinical studies, Janssen will take over development and then lead
More from news
Approximately 1 fully matching, plus 23 partially matching documents found.
Latest appointments
-
Kiadis Pharma appoints new chief operations officer
Prior to his time at Janssen, Feijen held positions for the likes of Crucell, Avebe and Gist Brocades.
-
Cell Medica adds to senior management team
He brings extensive experience in biotechnology manufacturing to the role, having held senior leadership positions at Crucell, Merck, Roche and Schering-Plough.
-
TiGenix appoints Dr Marie Paule Richard
TiGenix appoints Dr Marie Paule Richard. She takes on role as chief medical officer and brings experience from Aicuris and Crucell. ... pharmacovigilance and medical affairs at Crucell in Switzerland.
More from appointments
Approximately 1 fully matching, plus 2 partially matching documents found.
Featured jobs
- Business Unit Head, Medical Communications, London
-
Excellent package
-
Client Services Director - Med Comms
-
Great salary and bebefits
- Head of Market Access - International - Based Cambridge
-
Excellent Basic, Bonus and Flex Benefits
-
Senior Account Manager
-
Competitive salary commensurate with experience
- Strategic Planner, Healthcare Advertising
-
£47, 000 – £53, 000
- Home based, Chief Medical Writer, Medical Communications
-
Excellent package
- Principal Medical Writer / Editorial Director – Medical Communic...
-
£60, 000 - £80, 000
- Home based, Editorial Team Leader, Medical Communications
-
Excellent package
- Account Manager, Medical Communications and Marketing
-
£30, 000 – £40, 000 benefits and bonus
- Account Director, Medical Communications
-
C£50 – 65, 000 benefits and bonus
- Account Director, Consumer Healthcare PR, Global PR agency
-
£50, 000 – £58, 000
- Home based, Senior Medical Writer, Medical Communications
-
Excellent package
-
Healthcare PR Director
-
£100, 000 – £120, 000 benefits
-
Account Manager
-
£40, 000 - £45, 000 benefits
- Senior Medical Writer, Healthcare Advertising Agency
-
£45, 000 – £50, 000
- Home based, Principal Medical Writer, Medical Communications
-
Excellent package
Subscribe to our email news alerts
- Moving annual total (MAT)
- Brexit rebels win vote on European Medicines Agency alignment
- Communiqué Awards 2018: Photo Gallery - Communiqué Awards 2016
- MaxCyte gets green light for solid tumour cell therapy
- NHS England to Vertex: come clean on Orkambi offer
- GSK sells eczema and psoriasis drug to Dermavant for £250m
- Random42 win Creativity International Award for Scientific Animation
- Merck & Co joins big pharma pricing pledge – but sceptics unconvinced
- Aurora partners with PIPHealth and taps into patient panels
- FDA’s Gottlieb lambasts industry’s biosimilar-blocking tactics
- Allergan’s abicipar matches AMD blockbuster Lucentis in phase III
- OUTiCO growth in multi-channel creates more job openings
PMHub
SpotMe
SpotMe is the leading technology and service provider of enterprise engagement platforms with a focus on live events, virtual and...
Latest intelligence
- Developing advocacy in the pharmaceutical industry.
- The importance of advocacy programmes...
- GDPR and events. What does the pharma industry need to know?
- Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
- Digital trends in B2B sales - how far behind is Pharma?
- The modern approach to B2B sales is data-driven, and enabled by digital tools....
Quick links
Infographics
